Therapeutic options for Parkinson’s disease patients are limited to cholinesterase inhibitors,112 which may be transient to replace the impaired cholinergic transmission.113 Also, it is still under debate whether dopamine replacement medications have cognitive side effects114 while improving motor symptoms in cognitively impaired Parkinson’s disease patients. Here, BCHE is linked to Parkinson disease.